Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gw572016 (17) 17
humans (13) 13
lapatinib (12) 12
breast cancer (10) 10
egfr (10) 10
life sciences & biomedicine (10) 10
science & technology (10) 10
quinazolines - therapeutic use (8) 8
female (7) 7
her2 (7) 7
biological and medical sciences (6) 6
breast neoplasms - drug therapy (6) 6
medical sciences (6) 6
pharmacology & pharmacy (6) 6
antineoplastic agents (5) 5
antineoplastic agents - therapeutic use (5) 5
oncology (5) 5
pharmacology. drug treatments (5) 5
quinazolines - pharmacokinetics (5) 5
quinazolines - pharmacology (5) 5
receptor, erbb-2 - antagonists & inhibitors (5) 5
antimitotic agents (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cancer (4) 4
clinical trials as topic (4) 4
dual tyrosine kinase inhibitor (4) 4
erbb2 (4) 4
protein kinase inhibitors - therapeutic use (4) 4
quinazolines - adverse effects (4) 4
research (4) 4
signal transduction (4) 4
trastuzumab (4) 4
tumors (4) 4
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
breast neoplasms - metabolism (3) 3
chemotherapy (3) 3
dosage and administration (3) 3
gefitinib (3) 3
gynecology. andrology. obstetrics (3) 3
her-2 (3) 3
mammary gland diseases (3) 3
metastasis (3) 3
metastatic breast cancer (3) 3
neoplasms - drug therapy (3) 3
receptor protein-tyrosine kinases - antagonists & inhibitors (3) 3
receptor, epidermal growth factor - antagonists & inhibitors (3) 3
tyrosine (3) 3
tyrosine kinase inhibitor (3) 3
animals (2) 2
antibodies, monoclonal, humanized (2) 2
antineoplastic agents - pharmacokinetics (2) 2
area under curve (2) 2
breast neoplasms - pathology (2) 2
capecitabine (2) 2
care and treatment (2) 2
cell line, tumor - drug effects (2) 2
ci-1033 (2) 2
complications and side effects (2) 2
drug resistance, neoplasm (2) 2
enzyme inhibitors (2) 2
epidermal growth factor (2) 2
erbb-2 (2) 2
erbb1 (2) 2
erlotinib (2) 2
health aspects (2) 2
internal medicine (2) 2
medical education (2) 2
medicine & public health (2) 2
oncology, experimental (2) 2
protein kinase inhibitors - adverse effects (2) 2
protein kinase inhibitors - pharmacokinetics (2) 2
proteins (2) 2
quinazolines - administration & dosage (2) 2
radiotherapy (2) 2
skin and connective tissue diseases (2) 2
administration, oral (1) 1
adolescent (1) 1
adult (1) 1
adverse events (1) 1
akt (1) 1
analysis (1) 1
analytical, structural and metabolic biochemistry (1) 1
ancer treatment (1) 1
antibodies, monoclonal - pharmacology (1) 1
antibodies, monoclonal - physiology (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
apoptosis - drug effects (1) 1
binding sites (1) 1
biochemical research methods (1) 1
biochemistry & molecular biology (1) 1
bms 247550 (1) 1
breast neoplasms - enzymology (1) 1
breast neoplasms - genetics (1) 1
breast neoplasms - radiotherapy (1) 1
cancer therapies (1) 1
cell cycle - drug effects (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
by Medina, Patrick J., PharmD, BCOP and Goodin, Susan, PharmD, FCCP, BCOP
Clinical therapeutics, ISSN 0149-2918, 2008, Volume 30, Issue 8, pp. 1426 - 1447
Internal Medicine | Medical Education | dual-receptor inhibitor | GW572016 | lapatinib | pharmacokinetics | clinical trials | adverse events | HER2 | EGFR | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Area Under Curve | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme System - metabolism | Half-Life | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Clinical Trials, Phase III as Topic | Drug Interactions | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Quinazolines - pharmacology | Clinical Trials, Phase II as Topic | Antimitotic agents | Tyrosine | Care and treatment | Epidermal growth factor | Phenols | Metastasis | Phosphotransferases | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
by Rita Nahta and Linda X.H. Yuan and Yi Du and Francisco J. Esteva
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2007, Volume 6, Issue 2, pp. 667 - 674
Herceptin | ErbB-2 | IGF-I receptor | GW572016 | αIR3 | Life Sciences & Biomedicine | Oncology | Science & Technology | Receptor, IGF Type 1 - metabolism | Immunoprecipitation | Signal Transduction | Apoptosis - drug effects | Antibodies, Monoclonal - pharmacology | Humans | Drug Resistance, Neoplasm | Immunoblotting | Cell Line, Tumor - drug effects | Breast Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized | Breast Neoplasms - pathology | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Receptor, ErbB-2 - antagonists & inhibitors | Cell Cycle - drug effects | Quinazolines - pharmacology | Insulin-Like Growth Factor I - metabolism | Trastuzumab | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer
by Tevaarwerk, Amye J., MD and Kolesar, Jill M., PharmD
Clinical therapeutics, ISSN 0149-2918, 2009, Volume 31, Issue 2, pp. 2332 - 2348
Internal Medicine | Medical Education | ErbB2 | ErbB1 | GW572016 | dual tyrosine kinase inhibitor | lapatinib | HER2 | Tykerb | EGFR | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Protein Kinase Inhibitors - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Humans | Quinazolines - pharmacokinetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Protein Kinase Inhibitors - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Quinazolines - pharmacology | Breast Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors
by Rowinsky, Eric K
Annual review of medicine, ISSN 0066-4219, 2004, Volume 55, Issue 1, pp. 433 - 457
Gefitinib | GW572016 | Erlotinib CI-1033 | EGFR | Epidermal growth factor receptor | EKB-569 | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neoplasms - therapy | Humans | Receptor Protein-Tyrosine Kinases - physiology | Antibodies, Monoclonal - physiology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Signal Transduction - physiology | Neoplasms - physiopathology | Research | Therapeutics | Homeopathy | Materia medica and therapeutics | Proteins | Medical research | Drug therapy | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Lapatinib: Current Status and Future Directions in Breast Cancer
by Moy, Beverly and Goss, Paul E
The oncologist (Dayton, Ohio), ISSN 1083-7159, 11/2006, Volume 11, Issue 10, pp. 1047 - 1057
GW572016 | ErbB‐1 | ErbB‐2 | Breast cancer | Lapatinib | HER‐2 | Dual tyrosine kinase inhibitor | EGFR | ErbB-2 | ErbB-1 | HER-2 | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Clinical Trials as Topic | Protein Kinase Inhibitors - adverse effects | Receptor Protein-Tyrosine Kinases - metabolism | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Breast Neoplasms - enzymology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Chemotherapy, Adjuvant | Heart Diseases - chemically induced | Trastuzumab | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors
by Nelson, Michael H and Dolder, Christian R
The Annals of pharmacotherapy, ISSN 1060-0280, 02/2006, Volume 40, Issue 2, pp. 261 - 269
Breast cancer | Lapatinib | HER2 | GW572016 | Dual tyrosine kinase inhibitor | EGFR | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Medical sciences | Pharmacology. Drug treatments | Tumors | Protein Kinase Inhibitors - pharmacokinetics | Humans | Neoplasms - enzymology | Quinazolines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Protein Kinase Inhibitors - adverse effects | PubMed | Neoplasms - drug therapy | Animals | Antineoplastic Agents - adverse effects | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Drug Design | Quinazolines - adverse effects | Antineoplastic Agents - pharmacokinetics | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Lapatinib in breast cancer
by Bilancia, D and Rosati, G and Dinota, A and Germano, D and Romano, R and Manzione, L
Annals of oncology, ISSN 0923-7534, 6/2007, Volume 18, Issue suppl_6, pp. vi26 - vi30
Breast cancer | Lapatinib | HER2 | GW572016 | Dual tyrosine kinase inhibitor | EGFR | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | Humans | Quinazolines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Randomized Controlled Trials as Topic | Animals | Antineoplastic Agents - adverse effects | Quinazolines - therapeutic use | Quinazolines - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Quinazolines - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
by Bence, Aimee K and Anderson, Eric B and Halepota, Maqbool A and Doukas, Michael A and DeSimone, Phillip A and Davis, George A and Smith, Deborah A and Koch, Kevin M and Stead, Andrew G and Mangum, Steve and Bowen, Carolyn J and Spector, Neil L and Hsieh, Showchien and Adams, Val R
Investigational new drugs, ISSN 0167-6997, 1/2005, Volume 23, Issue 1, pp. 39 - 49
Medicine & Public Health | GW572016 | signal transduction | Oncology | phase I | tyrosine kinase inhibitor | Pharmacology/Toxicology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Double-Blind Method | Administration, Oral | Area Under Curve | Humans | Middle Aged | Quinazolines - pharmacokinetics | Male | Cross-Over Studies | Maximum Tolerated Dose | Adolescent | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Safety | Antimitotic agents | Tyrosine | Complications and side effects | Dosage and administration | Research | Antineoplastic agents | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer
by Nelson, Michael H and Dolder, Christian R
Therapeutics and clinical risk management, ISSN 1176-6336, 2007, Volume 3, Issue 4, pp. 665 - 673
Breast cancer | Lapatinib | GW572016 | Tyrosine kinase inhibitor | lapatinib | breast cancer | Review | tyrosine kinase inhibitor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer
by Sardesai, Sagar D and Storniolo, Anna Maria
Women's health (London, England), ISSN 1745-5057, 06/2015, Volume 11, Issue 3, pp. 281 - 294
letrozole | trastuzumab | capecitabine | GW572016 | ERBB2 | metastatic breast cancer | lapatinib | HER-2 | Breast Neoplasms - genetics | Women's Health | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | United States | Humans | Postmenopause | Female | Antineoplastic Agents - therapeutic use | Receptor, ErbB-2 | Breast Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Dosage and administration | Enzyme inhibitors | Antineoplastic agents | Proteins | Signal transduction | Chemotherapy | Womens health | Medical prognosis | Ligands | Breast cancer | Metastasis | Kinases | Cancer therapies | Binding sites | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights